Calcium: The Darth Vader of ALS

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 2, Issue SUPPL. 1, 2001, Pages 47-54

  Appel, Stanley H ^a   Beers, David ^a   Siklos, Laszlo ^a   Engelhardt, Joseph I ^a   Mosier, Dennis R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

ALS; Calcium; Calcium binding; Motor neurons; Parvalbumin; Proteins; Selective vulnerability

Indexed keywords

AMPA RECEPTOR; CALBINDIN; CALCIUM; CALCIUM BINDING PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; KAINIC ACID RECEPTOR; PARVALBUMIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; ION PERMEABILITY; MISSENSE MUTATION; MITOCHONDRION SWELLING; MOTONEURON; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0035016989     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/146608201300079418     Document Type: Article

References (86)

1. Hirano A. Cytopathology of amyotrophic lateral sclerosis. In: Rowland LP, ed. Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases, Vol 56. New York: Raven Press, 1991: 91-101.
2. Leigh PN, Swash M. Cytoskeletal pathology in motor neuron disease. In: Rowland LP, ed. Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases, Vol 56. New York: Raven Press, 1991: 115-124.
3. Choi DW. Excitotoxic cell death. J Neurobiol 1992; 23: 1261-1276.
4. Siklos L, Engelhardt J, Harati Y, Smith RG, Joo F, Appel SH. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 996; 39: 203-216.
5. Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20: 589-602.
6. Rothstein JD, Martin LI, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326: 1464-1468.
7. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18-25.
8. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993; 61: 2322-2325.
9. Siklos L, Engelhardt JI, Alexianu ME, Gurney ME, Siddique T, Appel SH. Intracellular calcium parallels motor neuron degeneration in SOD-1 mutant mice. J Neuropathol Exp Neurol 1998; 57: 571-587.
10. +: implications for neurodegeneration. J Neurochem 1994; 63: 584-591.
11. + rises and consequent oxygen radical production. J Neurosci 1998; 18: 7727-7738.
12. Dugan LL, Sensi SL, Canzoniero LM, et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci 1995; 15: 6377-6388.
13. Coyle JT, Putterfarcken P. Oxidation stress, glutamate and neurodegenerative disorders. Science 1993; 146: 354-360.
14. Tymianski M, Charlton MP, Carlen PL, Tator CH. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 1993; 13: 2085-2104.
15. Kakkar P, Mehrotra S, Viswanathan PN. Interrelation of active oxygen species, membrane damage and altered calcium functions. Mol Cell Biochem 1992; 111: 11-15.
16. Engelhardt JI, Siklos L, Komuves L, Smith RG, Appel SH. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motor neurons. Synapse 1995; 20: 185-199.
17. Pullen AH, Humphreys P. Ultrastructural analysis of spinal motor neurons from mice treated with IgG from ALS patients, healthy individuals, or disease controls. J Neurol Sci 2000; 180: 34-45.
18. Appel SH, Engelhardt JI, Garcia J, Stefani E. Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc Natl Acad Sci USA 1991; 88: 647-651.
19. Mosier DR, Siklos L, Appel SH. Resistance of extraocular motor neuron terminals to effects of amyotrophic lateral sclerosis sera. Neurology 2000; 54: 252-255.
20. O'Shaughnessy TJ, Yan H, Kim J, et al. Amyotrophic lateral sclerosis: serum factors enhance spontaneous and evoked transmitter release at the neuromuscular junction. Muscle Nerve 1998; 21: 81-90.
21. Fratantoni SA, Weisz G, Pardal AM, Reisin RC, Uchitel OD. Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker. Muscle Nerve 2000; 23: 543-550.
22. + currents in motor neuron cell line. Ann Neurol 1995; 37: 102-109.
23. Colom LV, Alexianu ME, Mosier DR, Smith RG, Appel SH. Amyotrophic lateral sclerosis immunoglobulins increase intracellular calcium in a motor neuron cell line. Exp Neurol 1997; 146: 354-360.
24. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
25. Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993; 261: 1047-1051.
26. Boukaftane Y, Khoris J, Moulard B, et al. Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci 1998; 25: 192-196.
27. Cleveland DW. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 1999; 24: 515-520.
28. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-1116.
29. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
30. Borchelt DR, Lee MK, Slunt HS, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 1994; 91: 8292-8296.
31. Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-338.
32. Williams TL, Day NC, Ince PG, Kamboj RK, Shaw PJ. Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997; 42: 200-207.
33. Puchalski RB, Louis JC, Brose N, et al. Selective RNA editing and subunit assembly of native glutamate receptors. Neuron 1994; 13: 131-147.
34. Morrison BM, Janssen WG, Gordon JW, Morrison JH. Light and electronic microscopic distribution of the AMPA receptor subunit GluR2 in the spinal cord of contral and G86R mutant superoxide dismutase transgenic mice. J Comp Neurol 1998; 395: 523-534.
35. Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1999; 46: 806-815.
36. 2+ permeable AMP or kainate receptors: possible key factors in selective neurodegeneration. Trends Neurosci 2000; 23: 365-371.
37. +) overload and ROS generation in spinal motor neurons in vitro. J Neurosci 2000; 20: 240-250.
38. Vandenberghe W, Robberecht W, Brorson JR. AMPA receptor calcium permeability, GluR2 expression, and selective motor neuron vulnerability. J Neurosci 2000; 20: 123-132.
39. Celio MR. Calbindin D-28k and parvalbumin in the rat nervous system. Neuroscience 1990; 35: 375-475.
40. Celio MR, Baier W, Scharer L, de Viragh PA, Gerday C. Monoclonal antibodies directed against the calcium binding protein parvalbumin. Cell Calcium 1988; 9: 81-86.
41. Dreessen J, Lutum C, Schafer BW, Heizmann CW, Knopfel T. Alpha-parvalbumin reduces depolarization-induced elevations of cytosolic free calcium in human neuroblastoma cells. Cell Calcium 1996; 19: 527-533.
42. 28K and parvalbumin in rat sensory neurones. J Physiol 1993; 472: 341-357.
43. Lledo PM, Somasundaram B, Morton AJ, Emson PC, Mason WT. Stable transfection of calbindin-D28K into the GH3 cell line alters calcium currents and intracellular calcium homeostasis. Neuron 1992; 9: 943-954.
44. Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci USA 1996; 93: 5709-5714.
45. Appel, SH. Excitotoxic neuronal cell death in amyotrophic lateral sclerosis. Trends Neurosci 1993; 16: 3-4.
46. DePaul R, Abbs JH, Caligiuri M, Gracco VL, Brooks BR. Hypoglossal, trigeminal, and facial motor neuron involvement in amyotrophic lateral sclerosis. Neurology 1988; 38: 281-283.
47. Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH. The role of calcium-binding proteins in selective motor neuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994; 36: 846-858.
48. Appel SH, Engelhardt J, Smith RG, Stefani E. Theories of causation. In: Leigh PN, Swash M, eds. Motor Neuron Disease: Theories of Causation. Berlin: Springer-Verlag, 1995; 219-240.
49. Reiner A, Medina L, Figueredo-Cardenas G, Anfinson S. Brainstem motor neuron pools that are selectively resistant in amyotrophic lateral sclerosis are preferentially enriched in parvalbumin: evidence from monkey brainstem for a calcium-mediated mechanism in sporadic ALS Exp Neurol 1995; 131: 239-250.
50. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995; 65: 643-651.
51. 2+ and protein kinase C. Trends Pharmacol Sci 1996; 17: 114-120.
52. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol 1997;244 (suppl 2): S3-S14.
53. Ince P, Stout N, Shaw P, et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993; 19: 291-299.
54. Elliott JL, Snider WD. Parvalbumin is a marker of ALS-resistant motor neurons. Neuroreport 1995; 6: 449-452.
55. 28K cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity. Proc Natl Acad Sci USA 1996; 93: 6796-6801.
56. Roy J, Minotti S, Dong L, Figlewicz DA, Durham HD. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J Neurosci 1998; 18: 9673-9684.
57. Siklos L, Engelhardt JI, Adalbert R, Appel, SH. Calcium-containing endosomes at oculomotor terminals in animal models of ALS. Neuroreport 1999; 10: 2539-2545.
58. Nicholls DG, Ward MW. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci 2000; 23: 166-174.
59. Vanselow BK, Keller BU. Calcium dynamics and buffering in oculomotor neurons from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motor neuron disease. J Physiol (Lond) 2000; 525: 433-445.
60. Lips MB, Keller BU. Activity-related calcium dynamics in motor neurons of the nucleus hypoglossus from mouse. J Neurophysiol 1999; 82: 2936-2946.
61. Palecek J, Lips MB, Keller BU. Calcium dynamics and buffering in motor neurons of the mouse spinal cord. J Physiol (Lond) 1999; 520: 485-502.
62. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med 1999; 5: 347-350.
63. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
64. Nicholls DG, Budd SL Mitochondria and neuronal survival. Physiol Rev 2000; 80: 315-360.
65. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1998; 1366: 211-223.
66. Wiedemann FR, Winkler K, Kuznetsov AV, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998; 156: 65-72.
67. Sasaki S, Iwata M. Impairment of fastaxonal transport in proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 1996; 47: 535-540.
68. Brown RH Jr, Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064-2074.
69. Fujita K, Yamauchi M, Shibayama K, Ando M, Honda M, Nagata Y. Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis. J Neurosci Res 1996; 45: 276-281.
70. Curti D, Malaspina A, Facchetti G, et al. Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology 1996; 47: 1060-1064.
71. Miller SW, Trimmer PA, Parker WD Jr, Davis RE. Creation and characterization of mitochondrial DNA-depleted cell lines with 'neuronal-like' properties. J Neurochem 1996; 67: 1897-1907.
72. Swerdlow RH, Parks JK, Cassarino DS, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol 1998; 153: 135-142.
73. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999; 46: 787-790.
74. Kaal EGA, Vlug AS, Versleijen MWJ, Kuilman M, Joosten EAJ, Bär PR. Chronic mitochondrial inhibition induces selective motor neuron death in vitro: a new model for amyotrophic lateral sclerosis. J Neurochem 2000; 74: 1158-1165.
75. Nakano Y, Hirayama K, Terao K. Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch Neurol 1987; 44: 103-106.
76. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998; 18: 3241-3250.
77. Dal Canto MC, Gurney ME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 1994; 145: 1271-1279.
78. 2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett 1997; 414: 365-368.
79. Bolanos JP, Heales SJ, Land JM, Clark JB. Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture. J Neurochem 1995; 64: 1965-1972.
80. Szatkowski M, Atwell D. Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 1994; 17: 359-365.
81. Rothman S. Excitotoxic neuronal death: mechanisms and clinical relevance. Sem Neurosci 1994; 6: 315-322.
82. Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364: 626-632.
83. Heizmann CW, Braun K. Changes in Ca(2+)-binding proteinsin human neurodegenerative disorders. Trends Neurosci 1992; 15: 259-264.
84. Waldvogel HJ, Faull RL, Williams MN, Dragunow M. Differential sensitivity of albindin and parvalbumin immunoreactive cells in the striatum to excitotoxins. Brain Res 1991; 546: 329-335.
85. Fukuda T, Adachi E, Kawashima S, Yoshiya I, Hashimoto PH. Immunohistochemical distribution of calcium-activated neutral proteinases and endogenous CANP inhibitor in the rabbit hippocampus. J Comp Neurol 1990; 302: 100-109.
86. 28K: a potential neuroprotective protein. Neurodegeneration 1994; 3: 1-20.